Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KT050
- Development stage
- Preclinical
- Lead developer
- Nanjing Kati Medical Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KT050 is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy currently in preclinical development by Nanjing Kati Medical Technology. The program is designed to target solid tumors, with specific focus on indications such as glioblastoma (GBM), small-cell lung cancer (SCLC), liver cancer, breast cancer, medulloblastoma, and lung squamous cell carcinoma. As a second-generation CAR-T, it likely incorporates a costimulatory domain alongside the CD3ζ signaling domain to enhance T-cell proliferation and persistence. The specific antigen target for KT050 has not been publicly disclosed by the developer.
Beyond the preview
Go deeper on KT050.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KT050.